bafilomycin A1
Catalog No: FT-0699152
CAS No: 88899-55-2
- Molecular Formula: 622.8
- Formula Weight: C35H58O9
- Inchl Key: XDHNQDDQEHDUTM-JQWOJBOSSA-N
- Inchl: InChI=1S/C35H58O9/c1-19(2)32-24(7)27(36)18-35(40,44-32)26(9)31(38)25(8)33-28(41-10)14-12-13-20(3)15-22(5)30(37)23(6)16-21(4)17-29(42-11)34(39)43-33/h12-14,16-17,19,22-28,30-33,36-38,40H,15,18H2,1-11H3/b14-12+,20-13+,21-16+,29-17-/t22-,23+,24-,25-,26-,27+,28-,30-,31+,32+,33+,35+/m0/s1
Assay | Pack | Price | Stock | Action |
---|---|---|---|---|
98% | 1g | N/A | N/A | |
98% | 5g | N/A | N/A | |
98% | Bulk Quantity | N/A | N/A |
Melting_Point: | N/A |
---|---|
CAS: | 88899-55-2 |
MF: | C35H58O9 |
Flash_Point: | 232.2±26.4 °C |
Product_Name: | Bafilomycin A1 |
Density: | 1.1±0.1 g/cm3 |
FW: | 622.830 |
Bolling_Point: | 770.1±60.0 °C at 760 mmHg |
Refractive_Index: | 1.535 |
---|---|
Vapor_Pressure: | 0.0±6.0 mmHg at 25°C |
Flash_Point: | 232.2±26.4 °C |
LogP: | 3.88 |
Bolling_Point: | 770.1±60.0 °C at 760 mmHg |
FW: | 622.830 |
PSA: | 134.91000 |
Computational_Chemistry: | ['1 . XlogP 6 ', '2 . Hydrogen Bond Donor Count 4 ', '3 . Hydrogen Bond Acceptor Count 9 ', '4 . Rotatable Bond Count 7 ', '5 . Isotope Atom Count ', '6 . TPSA 135 ', '7 . Heavy Atom Count 44 ', '8 . Topological Polar Surface Area 0 ', '9 . Complexity 1060 ', '10. Isotope Atom Count 0 ', '11. Defined Atom Stereocenter Count 12 ', '12. Undefined Atom Stereocenter Count 0 ', '13. Defined Bond Stereocenter Count 4 ', '14. Undefined Bond Stereocenter Count 0 ', '15. Covalently-Bonded Unit Count 1'] |
MF: | C35H58O9 |
Exact_Mass: | 622.408081 |
Molecular_Structure: | ['1 . Molar refractive index 17194 ', '2 . Molar volume (m3/mol)5523 ', '3 . Parachor (902K)14388 ', '4 表面张力(dyne/cm)460 ', '5 . Polarizability (10-24cm3)6816'] |
Density: | 1.1±0.1 g/cm3 |
Hazard_Class: | 6.1(b) |
---|---|
Risk_Statements(EU): | R36/37/38 |
Personal_Protective_Equipment: | dust mask type N95 (US);Eyeshields;Gloves |
RIDADR: | UN 3172 |
Hazard_Codes: | Xi: Irritant; |
Safety_Statements: | 26-36 |
Packing_Group: | III |